HospitalsAescia for Hospitals is an investigational Software as a Medical Device under the TGA Class IIa pathway. Not yet available for commercial supply.
ClinicsAescia for Clinics is a workflow and patient-preparation tool. It does not propose clinical decisions and is not a medical device.
We publish plainly. No press copy, no launch videos, no "we are thrilled" posts. Just dated entries when something real happened.
Aescia has joined the Medical Technology Association of Australia's MedTech Compass program, which supports Australian medtech companies moving from concept to commercial adoption across regulatory, reimbursement, and clinical evidence.
Published the operating team, added trial-site and research-institute affiliations, unified the contact flow, and started this updates log. Clinic pricing posture stays explicit: flat monthly by specialty, no seat-based math.
The SAFE-Discharge trial at Royal Prince Alfred Hospital has cleared human research ethics review. Site-specific governance and IT assessments follow. No trial recruitment on this site; enrolment happens through the RPAH cardiothoracic unit under ethics approval.
Aescia joined the Product-Market-Fit programme at the CHEO Research Institute in Ottawa, with a paediatric-respiratory post-discharge pathway as the working focus. Four candidate specialties under evaluation inside the programme: paediatric respiratory, paediatric cardiothoracic adjacency, paediatric gastroenterology, and paediatric oncology.
Compiled a ten-document evidence base covering international guidelines, digital interventions, operational economics, diabetes and anticoagulant management, GLP-1, and special populations for colonoscopy preparation. Underpins the clinician-authored prep pathway shipping with the first paying clinic.
End-to-end walkthrough across patient, clinician, and admin flows. Pathway authoring, multichannel reminders, GLP-1 overlay, diabetic and anticoagulant scenarios, recall tracking, and structured export. Production deploy follows once production database and EMR integration targets land.
Application MVPV25RD3347 lodged with Investment NSW on 10 April 2026. Matched-funding programme for targeted commercialisation work. Decision expected late June 2026.
Targeted Translation Research Accelerator application submitted. Three milestones, clinical evaluation and regulatory work, decision expected around September 2026.
Aescia participated in Concordia University's Beat the Odds hiring event through the District 3 Innovation Hub. The program connects Montreal students with early-stage startups; Aescia hired its first Beat the Odds intern through the initiative.
Aescia joined District 3, Concordia's innovation hub for bio, health, and high-tech startups. The programme provides coaching, mentorship, and access to Montréal's startup ecosystem.
Want to follow along? Write to us and we will put you on a short update list.
Request a briefing